Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) Revenue (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Revenue for 6 consecutive years, with $85.1 million as the latest value for Q4 2025.

  • Quarterly Revenue rose 8508900.0% to $85.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $85.2 million through Dec 2025, up 230194.59% year-over-year, with the annual reading at $85.2 million for FY2025, 230194.59% up from the prior year.
  • Revenue for Q4 2025 was $85.1 million at 4D Molecular Therapeutics, up from $90000.0 in the prior quarter.
  • The five-year high for Revenue was $85.1 million in Q4 2025, with the low at -$19000.0 in Q4 2023.
  • Average Revenue over 5 years is $6.4 million, with a median of $200500.0 recorded in 2022.
  • The sharpest move saw Revenue tumbled 101.52% in 2023, then surged 8508900.0% in 2025.
  • Over 5 years, Revenue stood at $92000.0 in 2021, then surged by 1255.43% to $1.2 million in 2022, then plummeted by 101.52% to -$19000.0 in 2023, then surged by 105.26% to $1000.0 in 2024, then soared by 8508900.0% to $85.1 million in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $85.1 million, $90000.0, and $15000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.